Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM MNC Transplantation for Cerebral Palsy Due to Brain Hypoxia
NCT06629324Phase 2Recruiting
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in cerebral palsy (CP), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Started Oct 2024; status: recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT06629324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629324.